Study shows long-lasting effects of HBV vaccines | WHO: Number of obese children may reach 70M by 2025 | Harvard physician envisions future uses for probiotics
Web Version
 
July 23, 2014
CONNECT WITH ACG®  FacebookTwitter
Digestive Health SmartBrief
From Stanley K. Fergus and the American College of Gastroenterology
SIGN UP|FORWARD|ADVERTISE

Top Story
Study shows long-lasting effects of HBV vaccines
Early hepatitis B vaccination offers children long-term protection and is well-tolerated, researchers reported. Emory University's Dr. Walter Orenstein said that the study shows "immunity to hepatitis B following a primary series in early childhood is long term and the data do not support a need for boosters with increasing time since vaccination." Medscape (free registration) (7/17)
Share: LinkedInTwitterFacebookGoogle+Email
Guide to Healthy Living
WHO: Number of obese children may reach 70M by 2025
A report by the World Health Organization says the number of obese children worldwide rose to 44 million in 2012 and is expected to increase to 70 million by 2025. Researchers stressed that childhood obesity requires a different intervention and treatment approach than obesity in adults. Voice of America (7/18)
Share: LinkedInTwitterFacebookGoogle+Email
Harvard physician envisions future uses for probiotics
Future research may show a role for probiotics in preventing obesity and allergies and treating autism symptoms, said Dr. Allan Walker of Harvard Medical School. He said while the scientific evidence is not yet sufficient to support probiotics for these conditions, researchers do know that gut bacteria are very important for health and may almost function as another organ system. LiveScience.com (7/18)
Share: LinkedInTwitterFacebookGoogle+Email
Study ties chronic hepatitis C to low muscle mass risk
An analysis of data from the National Health and Nutrition Examination Survey involving 18,513 patients showed those with chronic hepatitis C virus infection had a higher likelihood of having low muscle mass, an early marker of malnutrition, than those without the condition. "Low muscle mass is a modifiable risk factor that leads to worse health outcomes, and clinicians should consider evaluating the nutritional status of their chronic HCV-infected patients routinely to identify those at-risk," researcher Charitha Gowda said. Healio (free registration) (7/17)
Share: LinkedInTwitterFacebookGoogle+Email
Diagnosis & Treatment
Experts note treatment challenges in UC patients with diabetes
Data showed type 1 diabetes was the third most common comorbidity for ulcerative colitis, and the diseases share many complications. Researchers also stressed caution in using corticosteroids in UC patients with diabetes because the treatment may raise blood glucose levels. Healio (free registration) (7/17)
Share: LinkedInTwitterFacebookGoogle+Email
Treatment improves liver function in alcoholic hepatitis
Standard medical therapy plus granulocyte colony-stimulating factor improved liver function and overall survival of patients with severe alcoholic hepatitis, according to a study in The American Journal of Gastroenterology. Healio (free registration) (7/18)
Share: LinkedInTwitterFacebookGoogle+Email
Raltegravir safe for end-stage liver disease and after transplant
Raltegravir was well-tolerated in patients with HIV who had liver transplants or end-stage liver disease, according to a 15-patient study. Among transplant patients, there were no interactions between immunosuppressive drugs and raltegravir. Healio (free registration)/Infectious Disease News (7/15)
Share: LinkedInTwitterFacebookGoogle+Email
Sofosbuvir clears hepatitis C in HIV patients, study finds
Data revealed combining hepatitis C virus drug sofosbuvir with ribavirin helped clear the most common strain of HCV in 76% of newly treated patients with HIV. HCV complications are a major cause of death among patients with HIV. Bloomberg (7/20)
Share: LinkedInTwitterFacebookGoogle+Email
Clinical Trial Monitor
A selection of U.S. based clinical trials seeking participants
Microbiome test for the detection of colorectal polyps and cancer
District of Columbia, Maryland. clinicaltrials.gov
Share: LinkedInTwitterFacebookGoogle+Email
Tenofovir alafenamide versus tenofovir disoproxil fumarate for treatment of hepatitis B
California, Florida, Maryland, Michigan, New Jersey, New York, Pennsylvania, Texas, Virginia, Australia, Canada, China, France, Hong Kong, India, Italy, Japan, Korea, New Zealand, Poland, Romania, Russian Federation, Spain, Taiwan, Turkey, United Kingdom. clinicaltrials.gov
Share: LinkedInTwitterFacebookGoogle+Email
RAD001, FOLFOX and bevacizumab in treatment of colorectal carcinoma
Utah. clinicaltrials.gov
Share: LinkedInTwitterFacebookGoogle+Email
Adenoma and second primary prevention trial (PACES)
Alaska, Arizona, Arkansas, California, Colorado, Connecticut, Delaware, Florida, Georgia, Hawaii, Idaho, Illinois, Indiana, Iowa, Kansas, Kentucky, Louisiana, Maine, Maryland, Massachusetts, Michigan, Minnesota, Mississippi, Missouri, Montana, Nebraska, Nevada, New Hampshire, New Jersey, New York, North Carolina, North Dakota, Ohio, Oklahoma, Oregon, Pennsylvania, South Carolina, South Dakota, Tennessee, Texas, Vermont, Virginia, Washington, Wisconsin, Wyoming. clinicaltrials.gov
Share: LinkedInTwitterFacebookGoogle+Email
Antibody treatment for advanced celiac disease
Minnesota. clinicaltrials.gov
Share: LinkedInTwitterFacebookGoogle+Email
Did you know?
How age and family history affect UC risk
"Ulcerative colitis usually begins before the age of 30. But, it can occur at any age, and some people may not develop the disease until their 50s or 60s. ... Although whites have the highest risk of the disease, it can occur in any race. ... You're at higher risk if you have a close relative, such as a parent, sibling or child, with the disease." -- Mayo Clinic
Share: LinkedInTwitterFacebookGoogle+Email
The Last Word
News and information from the American College of Gastroenterology
Obesity: Do you know your GI risks?
Do you weigh more than you should? Losing weight is more than about looking good, it is about being healthy. If your goal is to shed excess pounds, you're not alone. Millions of people suffer from obesity, which, if left untreated, could potentially lead to serious health problems. From ACG, Obesity: Do You Know Your GI Risks?, will provide you information about obesity, its dangers, what you can do to improve your health and tools and tips to help you succeed.
Share: LinkedInTwitterFacebookGoogle+Email
SmartQuote
Be brave enough to start a conversation that matters."
-- Margaret Wheatley,
American writer
Share: LinkedInTwitterFacebookGoogle+Email
Contact Your Doctor
Stanley K. Fergus
Gastroenterolgy Associates of West Tennessee
1400 Kings Boulevard
Memphis, TN 38105

Phone: (901) 555-1234
 
Contact ACG
American College of Gastroenterology
P.O. Box 342260
Bethesda, MD 20827-2260
The presence of any advertisement in this newsletter does not constitute endorsement of the associated service, product, or company by the American College of Gastroenterology, SmartBrief, or any participating physicians.
The information contained in Digestive Health SmartBrief is not intended to be medical advice. Consult your physician before making any decisions regarding your health care.
Subscriber Tools
Please contact one of our specialists for advertising opportunities, editorial inquiries, job placements, or any other questions.
 
Editor:  Tara Rosenzweig
Advertising:  Rebecca Adelson
  P: 202.618.5665
 
 

Download the SmartBrief App  iTunes / Android
iTunes  Android
Mailing Address:
SmartBrief, Inc.®, 555 11th ST NW, Suite 600, Washington, DC 20004
© 1999-2014 SmartBrief, Inc.®
Privacy policy |  Legal Information